Olesen Sanne H, Zhu Jin-Yi, Martin Mathew P, Schönbrunn Ernst
Drug Discovery Department, Moffitt Cancer Center, Tampa, FL, 33612, USA.
Newcastle Cancer Centre, Newcastle University, Newcastle Upon Tyne, Tyne and Wear, NE2 4HH8, UK.
ChemMedChem. 2016 Jun 6;11(11):1137-44. doi: 10.1002/cmdc.201600115. Epub 2016 May 2.
Increasing evidence suggests key roles for members of the mammalian Sterile20-like (MST) family of kinases in many aspects of biology. MST3 is a member of the STRIPAK complex, the deregulation of which has recently been associated with cancer cell migration and metastasis. Targeting MST3 with small-molecule inhibitors may be beneficial for the treatment of certain cancers, but little information exists on the potential of kinase inhibitor scaffolds to engage with MST3. In this study we screened MST3 against a library of 277 kinase inhibitors using differential scanning fluorimetry and confirmed 14 previously unknown MST3 inhibitors by X-ray crystallography. These compounds, of which eight are in clinical trials or FDA approved, comprise nine distinct chemical scaffolds that inhibit MST3 enzymatic activity with IC50 values between 0.003 and 23 μm. The structure-activity relationships explain the differential inhibitory activity of these compounds against MST3 and the structural basis for high binding potential, the information of which may serve as a framework for the rational design of MST3-selective inhibitors as potential therapeutics and to interrogate the function of this enzyme in diseased cells.
越来越多的证据表明,哺乳动物不育20样(MST)激酶家族成员在生物学的许多方面发挥着关键作用。MST3是STRIPAK复合体的成员,该复合体的失调最近与癌细胞迁移和转移有关。用小分子抑制剂靶向MST3可能对某些癌症的治疗有益,但关于激酶抑制剂支架与MST3结合潜力的信息却很少。在本研究中,我们使用差示扫描荧光法针对277种激酶抑制剂库筛选了MST3,并通过X射线晶体学确认了14种先前未知的MST3抑制剂。这些化合物中有8种处于临床试验或已获FDA批准,它们包含9种不同的化学支架,以0.003至23μm的IC50值抑制MST3酶活性。构效关系解释了这些化合物对MST3的不同抑制活性以及高结合潜力的结构基础,这些信息可作为合理设计MST3选择性抑制剂作为潜在治疗药物的框架,并用于探究该酶在病变细胞中的功能。